Impact of 2018 EU Risk Minimisation Measures and Revised Pregnancy Prevention Programme on Utilisation and Prescribing Trends of Medicinal Products Containing Valproate: An Interrupted Time Series Study

[1]  Y. Goldberg,et al.  Effect size quantification for interrupted time series analysis: implementation in R and analysis for Covid-19 research , 2022, Emerging Themes in Epidemiology.

[2]  K. Bhaskaran,et al.  Investigating the optimal handling of uncertain pregnancy episodes in the CPRD GOLD Pregnancy Register: a methodological study using UK primary care data , 2022, BMJ Open.

[3]  Chihiro Nishikawa,et al.  Effectiveness of risk minimization measures for valproate: a drug utilization study based on implementation of a risk minimization programme in Europe, analysis of data from the UK , 2021, Current medical research and opinion.

[4]  M. Loane,et al.  From Inception to ConcePTION: Genesis of a Network to Support Better Monitoring and Communication of Medication Safety During Pregnancy and Breastfeeding , 2021, Clinical pharmacology and therapeutics.

[5]  A. Biraben,et al.  Impact of recommendations on sodium valproate prescription among women with epilepsy: An interrupted time-series study , 2021, Epilepsy & Behavior.

[6]  S. Tcherny-Lessenot,et al.  Effectiveness of risk minimisation measures for valproate: A cross‐sectional survey among physicians in Europe , 2020, Pharmacoepidemiology and drug safety.

[7]  H. D. de Voogd,et al.  Effectiveness of risk minimisation measures for valproate: A drug utilisation study in Europe , 2020, Pharmacoepidemiology and drug safety.

[8]  R. Green,et al.  Valproate and folate: Congenital and developmental risks , 2020, Epilepsy & Behavior.

[9]  C. Huerta,et al.  Base de Datos para la Investigación Farmacoepidemiológica en Atención Primaria (BIFAP): A data resource for pharmacoepidemiology in Spain , 2020, Pharmacoepidemiology and drug safety.

[10]  H. Dolk,et al.  The ENCePP Code of Conduct: A best practise for scientific independence and transparency in noninterventional postauthorisation studies , 2019, Pharmacoepidemiology and drug safety.

[11]  S. Kochen,et al.  Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry , 2018, The Lancet Neurology.

[12]  A. Wieck,et al.  Dangers of valproate in pregnancy , 2018, British medical journal.

[13]  P. Ryan,et al.  Inferring pregnancy episodes and outcomes within a network of observational databases , 2018, PloS one.

[14]  Dan Dediu,et al.  Computation of adherence to medication and visualization of medication histories in R with AdhereR: Towards transparent and reproducible use of electronic healthcare data , 2017, PloS one.

[15]  J. Clayton-Smith,et al.  Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. , 2016, The Cochrane database of systematic reviews.

[16]  Edoardo Vacchi,et al.  Data Extraction and Management in Networks of Observational Health Care Databases for Scientific Research: A Comparison of EU-ADR, OMOP, Mini-Sentinel and MATRICE Strategies , 2016, EGEMS.

[17]  Guidelines for good pharmacoepidemiology practice (GPP) , 2016, Pharmacoepidemiology and drug safety.

[18]  Sigrun Alba Johannesdottir Schmidt,et al.  The Danish National Patient Registry: a review of content, data quality, and research potential , 2015, Clinical epidemiology.

[19]  A. Sheikh,et al.  Smoke-free legislation and the incidence of paediatric respiratory infections and wheezing/asthma: interrupted time series analyses in the four UK nations , 2015, Scientific Reports.

[20]  Muhammad Mamdani,et al.  Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations. , 2015, Journal of clinical epidemiology.

[21]  K. Bhaskaran,et al.  Data Resource Profile: Clinical Practice Research Datalink (CPRD) , 2015, International journal of epidemiology.

[22]  J. Lei,et al.  Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how? , 2014, Journal of internal medicine.

[23]  C Barbui,et al.  What is the European Medicines Agency? , 2012, Epidemiology and Psychiatric Sciences.

[24]  R. Herings,et al.  Pharmacy-Based Medical Record Linkage Systems , 2012 .

[25]  J. Hallas,et al.  The Danish National Prescription Registry , 2011, Scandinavian journal of public health.

[26]  C. Pedersen,et al.  The Danish Civil Registration System , 2011, Scandinavian journal of public health.

[27]  H. Gardarsdottir,et al.  Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length. , 2010, Journal of clinical epidemiology.

[28]  J. Grimshaw,et al.  Experimental and quasi-experimental designs for evaluating guideline implementation strategies. , 2000 .

[29]  R. Herings,et al.  PHARMO Database Network , 2021 .

[30]  Canary Wharf,et al.  The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) , 2012 .